By Justin Petrone

Lab21, a Cambridge, UK-based medical diagnostics firm, this week acquired fungal disease test maker Myconostica for an undisclosed sum.

The acquisition gives Lab21 access to its first set of nucleic acid-based assays, including a growing menu of RT-PCR and microarray-based tests.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.